CTOs on the Move

Riddell Sports

www.riddell.com

 
Riddell Sports is a Elyria, OH-based company in the Manufacturing sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Carrubba

Carrubba Incorporated specializes in the creation of custom fragrances, flavors botanical extracts and natural deodorants for leading manufacturers around the world.

Teradyne

Teradyne, Inc. is an American automatic test equipment designer and manufacturer based in North Reading, Massachusetts. Teradyne`s high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

Higgins Analytical Inc

Higgins Analytical Inc is a Mountain View, CA-based company in the Manufacturing sector.

Armor All Professional

Armor All Professional is a Atlanta, GA-based company in the Manufacturing sector.

enVVeno

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company`s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe™. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently waiting for regulatory approval to begin the TAVVE first-in-human trial for enVVe.